New research shows that fecal transplants may boost the effectiveness of cancer immunotherapy drugs called PD-1 inhibitors.

A humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

While both are called medullary carcinoma, these cancers differ in many ways: ...

This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance ...

Finding out that you have cancer can be overwhelming. Disbelief is common. Other emotions soon follow. Hearing that you’ve been misdiagnosed, though -- that the cancer is not what your doctor ...

Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated ...

Activating these receptors is intended to spark an immune response that fights cancer. According to clinical ... by high microsatellite instability (MSI) and it’s a driver of certain ...

The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant ...

As a tumor-agnostic biomarker, MSI is relevant to a vast majority of cancer patients, with up to 13 million individuals worldwide potentially eligible for this diagnostic approach each year.